INTRODUCTION
============

Agomelatine is a melatonergic (MT1 and MT2 agonist) antidepressant with additional serotonin (5-HT-2C) antagonist properties.[@b1-cpn-14-351] This represents a novel pharmacology among antidepressants as agomelatine is the only antidepressant with melatonergic properties. The efficacy of agomelatine has been demonstrated at doses of 25--50 mg in patients with moderate to severe major depressive disorder (MDD).[@b2-cpn-14-351],[@b3-cpn-14-351]

There are a few studies comparing agomelatine with other antidepressants. In a comprehensive review of studies comparing agomelatine with selective serotonin reuptake inhibitor (SSRI) or venlafaxine, Guaiana *et al*.[@b4-cpn-14-351] revealed that agomelatine did not provide a significant advantage in efficacy but was better tolerated than paroxetine and venlafaxine. However some of the studies in this review were unpublished and also most of them were sponsored by the pharmaceutical company. Based on a pooled analysis of four randomized clinical trials of agomelatine versus escitalopram, fluoxetine and sertraline, Demyttenaere *et al*.[@b5-cpn-14-351] concluded that agomelatine is at least as efficacious as SSRIs with a trend to fewer discontinuations due to adverse events. A randomised, double-blind study comparing efficacy and tolerability of agomelatine with fluoxetine showed that agomelatine and fluoxetine were equally effective in the treatment of MDD-associated symptoms and agomelatine showed good tolerability profile and safety.[@b6-cpn-14-351] In a long term (24 week), randomized, controlled and double-blind study comparing agomelatine with escitalopram, it is reported that agomelatine provides comparable antidepressant efficacy with better safety and tolerability profile and favourable effetcs on sleep-awake conditions.[@b7-cpn-14-351]

In our opinion, studies on efficacy and tolerability of agomelatine is not sufficient so far and more comparative studies with widely used antidepressants is needed. In this open-labeled, 12 weeks follow-up study, we aimed to compare the efficacy and tolerability of agomelatine with a widely used antidepressant sertraline.

METHODS
=======

Study Design and Materials
--------------------------

This study was carried out in the outpatient clinic of Haydarpasa Numune Training and Research Hospital between February 2013 and March 2014. Firstly, ethical comittee approval was obtained from the institute (HNEAH-KAEK-2012/85). Among the outpatients admitted to adult psychiatry clinic who have diagnosed as "major depressive episode" by clinician according to Diagnostic and Statistical Manual of Mental Disorders 4th edition and prescribed agomelatine (25 mg/day) or sertraline (50 mg/day) were included in the study. The other inclusion criteria were; to have a new onset depression and using none of psychotropic drugs recently (at least in the last month), to have none of chronic physical diseases, mental retardation and comorbid psychiatric diseases. Pregnant and puerperal patients and patients with suicidal ideas were also excluded from the study. The patients who accepted to participate in the study and signed written informed consent were included in the study. A second clinician, who is blind for the drug, performed the assessments of the study. Thereby first clinician maintained the clinical follow-up while second clinician maintained the assessments.

On the first interview, efficacy assessments were performed with Montgomery-Asberg Depression Rating Scale (MADRS),[@b8-cpn-14-351] Turkish version[@b9-cpn-14-351] and Clinical Global Impression (CGI) scale.[@b10-cpn-14-351] Further assessments were performed at 1st, 2nd, 4th, 8th and 12th weeks of treatment. The UKU (Udvalget for Kliniske Undersegelser) Side Effect Rating Scale was used to assess the tolerability of drugs.[@b11-cpn-14-351]

During the follow-up period 6 patients (4 patients from sertraline group and 2 patients from agomelatine group) who did not come to subsequent interviews and did not respond to the phone call excluded from the study. The study was terminated when the total number of patients completed the study is reached to 30 in both groups.

Statistics
----------

All statistical assessments were performed with IBM SPSS Statistics ver. 20.0 program (IBM Co., Armonk, NY, USA). Rates and frequencies are reported as raw numbers and percentages. We used chi-square tests with continuity correction for 2×2 tables to examine for possible differences in the categorical variables. Fisher's exact test was used instead of chi-square test when a 2×2 table had a cell with an expected frequency of less than 5. We used *t*-tests for independent groups to evaluate differences in the continuous variables and also Mann-Whitney *U*-test is used regarding the distribution of continuous variables. After checking the preliminary assumptions, repeated measures analysis of variance (ANOVA) with simple contrasts was performed on six consecutive measurements of MADRS to explore the main (group) and interaction (time by group) differences. Following a significant global F test, univariate ANOVAs with Greenhouse---Geisser adjustment was then used to assess the statistical significance if sphericity could not be assumed. Statistical significance is accepted as *p*\<0.05.

RESULTS
=======

The initial doses were 25 mg/day for agomelatine and 50 mg/day for sertraline. The mean doses at the end of follow-up period was 30.83±10.75 for agomelatine group and 59.16±17.95 for sertraline group which were both close to the initial doses. Three patients of sertraline group dropped-out from the study due to adverse effects. Two of them were due to gastrointestinal adverse effects like nausea and dyspepsia and one was due to sleeplessness. Any patient from agomelatine group dropped-out from the study due to adverse effects.

Comparison of demographical and clinical data of patients using sertraline or agomelatine is presented in [Table 1](#t1-cpn-14-351){ref-type="table"}. There were no difference between the groups in terms of age, sex, marital status, education level, occupation and the number of past depression episodes.

Comparison of CGI-Severity scale (CGI-S) and CGI-Improvement scale (CGI-I) scores of patient groups is shown in [Table 2](#t2-cpn-14-351){ref-type="table"}. Considering CGI-S scores, the only difference between sertraline and agomelatine groups was found at the third month, that the mean CGI-S scores of agomelatine group was higher than sertraline group. Mean CGI-I scores of sertraline group was higher than agomelatine group at the first week. However this finding reversed at the 8th week and mean CGI-I scores of agomelatine group was higher than sertraline group at the 8th and 12th weeks.

MADRS scores ≤8 is considered as 'remission', while more than 50% decline in MADRS score is considered as 'response' in this study. Comparison of remission and response rates of the study groups at the end of the study is shown in [Table 3](#t3-cpn-14-351){ref-type="table"}. Although the number of remitted patients in sertraline group was more than agomelatine group, the difference was not statistically significant. The number of patients responded to the treatment was equal across the groups.

Change of mean MADRS scores of the study groups in 3 months period has shown in [Figure 1](#f1-cpn-14-351){ref-type="fig"}. Mean MADRS scores of agomelatine and sertraline groups both decreased significantly at the end of 3 months follow-up (F=260.97, degree of freedom \[df\]=1, *p*\<0.001 for sertraline and F=455.96, df=1, *p*\<0.001 for agomelatine). The time by group interaction in MADRS scores was not significant at the end of 3 months follow-up (F=0.005, df=1, *p*=0.945). However the mean MADRS scores of agomelatine group significantly more declined from baseline than the sertraline group at the end of 2nd week (F=10.19, df=1, *p*=0.002). This difference disappared at the end of 4th week (F=1.954, df=1, *p*=0.167) and it has proceeded to the end of the follow-up.

Mean MADRS scores of sertraline and agomelatine groups were 23.23±6.51 and 26.63±5.24 respectively at the beginning of the study (*p*=0.030) and 8.40±5.46 and 11.66±6.94 respectively at the end of the study (*p*=0.048). The mean MADRS score of agomelatine group was higher than sertraline group both at the beginning and at the end of the study.

The comparison of side effects between study groups during the follow-up period has shown in [Table 4](#t4-cpn-14-351){ref-type="table"}. The sum of side effect scores at first week was higher in sertraline group than agomelatine group (*p*=0.015). This was mainly due to the more apparent autonomic side effects in sertraline group like reduced salivation (dry mouth), palpitations and increased sweating. Although the sum of psychiatric side effects were similar between groups, some psychiatric side effects like astenia and reduced sleep duration was higher in sertraline group (*p*=0.020 and *p*=0.024, respectively) at first week. The sum of side effect scores tend to decrease at 4th week in both groups and there were no significant difference between groups at 4th week (*p*=0.074). However, even side effect scores maintained decreasing in both groups, all group of side effects (except neurological side effects) were higher in sertraline group than agomelatine group at the end of 3 months period. There were no neurologic side effect in both groups at the end of the follow-up. Even it was rare, the main side effects in agomelatine group was sedation and increased duration of sleep particularly at the first week.

DISCUSSION
==========

Most of the comperative studies of agomelatine put forth similar efficacy,[@b7-cpn-14-351],[@b12-cpn-14-351]--[@b14-cpn-14-351] while some of the studies demonstrate superior efficacy[@b15-cpn-14-351],[@b16-cpn-14-351] of agomelatine to other commonly used antidepressants. Considering the efficacy data in this study, we found that mean MADRS scores of patients using agomelatine rapidly decreased in the first 2 weeks. However patients using sertraline respond the drug mainly after 2 weeks. Moreover better improvement scores with agomelatine has found in CGI-I in the first week. This early difference may be due to the well-known favourable effect of agomelatine on sleep related parameters.[@b17-cpn-14-351] This rapid effect on efficacy may be crucial for some critical situations like patients with suicidal tendencies. Nevertheless considering MADRS scores, the efficacy score of sertraline group was similar to agomelatine group at the end of first month and there were no difference in CGI-S and CGI-I scores between groups at that point. There were no difference between groups at the end of the study in terms of decline in MADRS scores. However considering CGI scores, sertraline group tend to demonstrate better improvement particularly after 2nd month. It is difficult to comment if the long term efficacy of sertraline would be better than agomelatine with this result because this finding is not confirmed with MADRS scores in this study and the duration of the study was not that long. Therefore in this point we may just highlight the need for long term studies to make a healthy interpretation. Although it was not statistically significant, the remission rate of sertraline group (46.7%) was higher than agomelatine group (33.3%) at the end of the study while the response rates were equal across groups (76.7%).

Most studies comparing agomelatine to other drugs have used Hamilton Rating Scale for Depression (HAM-D) scale for efficacy.[@b6-cpn-14-351],[@b13-cpn-14-351],[@b14-cpn-14-351],[@b16-cpn-14-351],[@b18-cpn-14-351],[@b19-cpn-14-351] In our opinion using MADRS or HAM-D is an other important issue that the percentage of items on sleep in HAM-D is more than in MADRS. It is very well documented that agomelatine improves sleep quality[@b7-cpn-14-351],[@b20-cpn-14-351],[@b21-cpn-14-351] and such differences may be considered when commenting on results. In a meta-analyses of randomized clinical trials of agomelatine comparing with other antidepressants, Huang *et al*.[@b21-cpn-14-351] revealed that even agomelatine shows a superior efficacy to other antidepressants, the difference in efficacy is not considered clinically relevant because of agomelatine's unique effect on sleep-awake conditions. We also support that idea and we believe that more data is needed to comment on particularly the long term efficacy of agomelatine.

Most of the clinical studies with agomelatine evidence the favourable tolerability profile of agomelatine in patients with depression.[@b6-cpn-14-351],[@b16-cpn-14-351],[@b22-cpn-14-351]--[@b25-cpn-14-351] In our opinion tolerability is the strong side of agomelatine. Kennedy *et al*.[@b12-cpn-14-351] revealed that the discontinuation due to adverse events was 2.2% with agomelatine in their study sample. It was remarkable that there was no patient dropped-out due to side effects in agomelatine group in our study. Some side effects mainly related with increased sedation were noticeable in agomelatine group particularly in the first week. At first week, psychiatric and autonomic side effects like astenia and reduced sleep duration, dry mouth, palpitations and increased sweating was higher in sertraline group. However two of three drop-outs from sertraline group were due to gastrointestinal side effects like nausea and dyspepsia. All side effects maintained decreasing in both groups during the follow-up period but it was remakable that almost all group of side effects (psychiatric, autonomic and other) were less in agomelatine group than sertraline group at the end of the follow-up and there was no neurological side effect in both groups. With this findings we assume that agomelatine has a spectacular tolerability profile and this profile seems to emerge even better during the later course of treatment.

In conlusion, comparing to sertraline, agomelatine has a rapid onset efficacy on depressive symptoms propably related with the improvement of sleep in patients with MDD and this can be beneficial for some particular cases. According to MADRS scores of this 3 months follow-up study agomelatine seems to have similar efficacy with sertraline. However considering CGI scores, we may suggest that studies investigating long term effects of agomelatine particularly on the core symptoms of depression other than vegetative symptoms would be beneficial. Agomelatine has a favourable tolerability profile both in terms of discontinuation and the amount of side effects comparing to sertraline. Relatively small number of patients, open-labeled design, lack of randomization and placebo-control are the main limitations of this study that limit the generalizability of the findings and further studies without these limitations are needed. Lack of assessing laboratory tests like blood liver enzymes is another limitation of this study that particularly agomelatine is associated with elevation of hepatic enzymes.[@b26-cpn-14-351]
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###### 

Comparison of demographical and clinical data of patients using sertraline or agomelatine

  Variable                   Sertraline (n=30)      Agomelatine (n=30)    *p* value
  -------------------------- ---------------------- --------------------- -----------
  Age (yr)                   35.16±12.08 (21--63)   34.16±8.84 (20--61)   0.716
  Sex (female:male)          21:9                   23:7                  0.559
  Marital status                                                          0.602
   Married                   16                     18                    
   Not married               14                     12                    
  Occupation                                                              0.196
   Employeed                 17                     12                    
   Not employeed             13                     18                    
  Education (yr)             7.73±4.66              7.96±4.49             0.844
  Past depression episodes   0.66±0.71              0.90±0.92             0.278

Values are presented as mean±standard deviation (range) or number only.

###### 

Comparison of mean CGI scores of the study groups

                     Sertraline (n=30)   Agomelatine (n=30)   *p* value
  ------------- ---- ------------------- -------------------- -----------
  CGI-S score                                                 
   Week         0    4.00±0.58           4.06±0.52            0.647
                1    3.83±0.69           3.73±0.78            0.837
                2    3.76±0.81           3.36±0.76            0.106
                4    3.26±0.94           3.16±0.91            0.801
                8    2.73±1.01           2.93±0.78            0.449
                12   2.00±0.90           2.66±0.95            0.008
  CGI-I score                                                 
   Week         1    3.66±0.47           3.33±0.60            0.015
                2    3.26±0.52           3.16±0.53            0.473
                4    2.83±0.53           3.06±0.78            0.278
                8    2.46±0.62           2.96±0.76            0.004
                12   1.96±0.76           2.76±1.07            0.002

Values are presented as mean±standard deviation.

CGI, Clinical Global Impression; CGI-S, CGI-Severity scale; CGI-I, CGI-Improvement scale.

###### 

Comparison of remission and response rates of the study groups

  Patient                    Sertraline (n=30)   Agomelatine (n=30)   *p* value
  -------------------------- ------------------- -------------------- -----------
  Remitted/nonremitted (n)   14/16               10/20                0.292
  Remission rate (%)         46.7                33.3                 
  Responded/nonresponded     23/7                23/7                 1
  Response rate (%)          76.7                76.7                 

###### 

Comparison of the side effects between study groups during the follow-up period

  UKU Side Effects Scale   Sertraline group (n=30)   Agomelatine group (n=30)   *p* value
  ------------------------ ------------------------- -------------------------- -----------
  Week 1                                                                        
   Psychiatric             2.06±1.83                 1.56±1.54                  0.259
   Neurologic              0.13±0.34                 0.06±0.25                  0.398
   Autonomic               2.33±1.66                 1.10±1.21                  0.002
   Other                   0.76±0.93                 0.50±0.73                  0.224
   Total                   8.23±3.64                 6.10±2.86                  0.015
  Week 4                                                                        
   Psychiatric             1.36±1.54                 0.96±1.40                  0.297
   Neurologic              0.06±0.25                 0.03±0.18                  0.562
   Autonomic               1.73±1.38                 1.26±1.25                  0.178
   Other                   0.90±0.84                 0.66±1.26                  0.406
   Total                   7.03±2.79                 5.66±3.02                  0.074
  Week 12                                                                       
   Psychiatric             0.76±1.13                 0.20±0.40                  0.014
   Neurologic              \-                        \-                         \-
   Autonomic               1.33±1.47                 0.40±0.81                  0.004
   Other                   0.63±0.76                 0.26±0.63                  0.049
   Total                   5.33±2.98                 3.30±1.68                  0.004

Values are presented as mean±standard deviation.

UKU, Udvalget for Kliniske Undersegelser.
